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The burden of neurodegenerative disorders in an aging population has become a challenge
for the modern world. While the biomarkers available and the methods of diagnosis have
improved to detect the onset of these diseases at early stages, the question of adapted
and efficient therapies is still a major issue. The prospect of replacing the loss of functional
neural cells remains an attractive but still audacious approach. A huge progress has been
made in the generation of neurons derived from human stem cell lines and transplantation
assays are tested in animals for a wide range of pathologies of the central nervous system.
Here we take one step back and examine neuronal differentiation and the characterization
of neural progenitors derived from human embryonic stem cells. We gather results
from our previous studies and present a cell model that was successfully used in
functional analyses and engraftment experiments. These neuronal precursors exhibit
spontaneous and evoked activity, indicating that their electrophysiological and calcium
handling properties are similar to those of matured neurons. Hence this summarized
information will serve as a basis to design better stem cell-based therapies to improve
neural regeneration.
Keywords: human embryonic stem cell, neural precursors, neurodegenerative diseases, spinal cord, immortalized
stem cell lines, calcium signaling, ion channels
INTRODUCTION
The present general interest in stem cell research results from
the promising dual perspective proposed by this advancing tech-
nology: on the one hand, it offers a source of in vitro models
for human cells that can mimic pathological states, and, on the
other hand, a possible therapeutic tool to induce cellular (and
tissue) regeneration. In both cases, the public organizations, cur-
rently trying to generate reliable stem cell registries, have to
face an increasing number of cell lines from all over the world.
Human embryonic stem cell (hESC) lines which can be commer-
cialized and used as candidates for cell therapies need to fulfill
a number of eligibility requirements starting from the moment
of tissue donation which are regulated by the NIH guidelines
on human stem cell research and by the U.S. Food and Drug
Administration (FDA). For example, the donors should fulfill the
eligibility requirements for tissue donors, including a number of
tests for infectious agents and diseases, which in many cases can
be hardly achieved due to some ethical and legal issues (for details,
see Jonlin, 2014).
The European hESC registry lists over 700 hESC lines and
52 human induced pluripotent stem cell (hiPSC) lines. The
International Stem Cell Registry, hosted by the University of
Massachusetts Worcester Campus, documents 1303 records for
hESCs and 281 records for hiPSCs. In addition, the NIH hESC
registry reports 261 cell lines having a registration number (see
also Adewumi et al., 2007). Beside the need for a unified inter-
national system to register the plethora of human stem cell lines
available at this date and in the future, these numbers high-
light the substantial variety of sources of starting material, and of
methods for cultivation, derivation and subculture. There is not
only multiplicity in the compounds and protocols used in stem
cell research, but also a disparity (leading sometimes to controver-
sies) in the experimental approaches to characterize these novel
cell lines.
Taking into account these real challenges as well as being aware
that not all of them can be currently solved, we propose the basic
steps necessary to create and select a putative human stem cell line
that could be employed for neural regeneration, especially with
regard to transplantation assays.
After injection in vivo, the cells in question should display the
ability to survive, proliferate, migrate, differentiate and maintain
a neural phenotype; conversely undifferentiated stem cells would
form tumors comprising of cells from all three embryonic germ
layers.
Many past and present studies have investigated the differ-
entiation of hESCs into the main neuronal and glial subtypes:
dopaminergic, GABA(γ-aminobutyric acid)ergic, glutamatergic
neurons, astrocytes, and oligodendrocytes. Whilst possible, the
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transplantation of terminally differentiated cells is difficult and
not ideal. Considering this the best option for cell therapy remains
the use of neural precursors (NPs); however, this method is not
without limitations as it is coupled with the risk of tumor for-
mation. Currently, there are not many reports available on tumor
prevention mechanisms. Several studies have demonstrated the
role of specific microRNAs (e.g., miR-302) in the control of
pluripotency (Eini et al., 2013). These findings, together with
future studies, may provide a means to control hESC tumori-
genicity and improve the safety of hESC with regard to therapeu-
tic use (Eini et al., 2013; Lin and Ying, 2013; Shah and Allegrucci,
2013).
CHOICE OF A CELL LINE: PRELIMINARY TESTS
The hESCs are prone to instability and variations; therefore their
culture is a challenging process. To assure the good quality of
hESCs, they have to meet the following critical criteria: (i) purity
(absence of any microbial contamination), (ii) identity (corre-
sponding to the correct profile of the cells), and (iii) stability
(the genotype and phenotype remain stable during passaging
in vitro). Particularly mycoplasma contamination may inhibit cell
growth, affect cell metabolism, and increase sensitivity to inducers
of apoptosis (Marx, 2014). Mycoplasmas are much smaller than
typical bacteria and the lack of cell walls makes these organisms
resistant to many antibiotics. There are a number of techniques
that are applied to mycoplasma detection. For routine testing
direct PCR or Hoechst 33258 staining have been used.
Using the CCTL14 hESC line as an example (Kozubenko et al.,
2010), after making sure that the cells have the expected kary-
otype, it is required to analyze the expression of several pluripo-
tent and neuroectodermal markers in undifferentiated hESCs
before starting the differentiation procedure. The undifferenti-
ated hESCs should express high levels of pluripotent markers such
as OCT-3/4 and Nanog, which are nuclear-localized transcrip-
tion factors, and SSEA-4, a surface antigen. Immunocytochemical
results demonstrated single CCTL14 cells in the colonies to be
positive for SSEA-1, whilst no positive staining was found for
NCAM, NF70, nestin, or β-III tubulin.
Single cell suspensions were labeled with antibodies directed
against Nanog, SSEA-4, SSEA-1, TRA-1-60, CD24, CD133, CD56
(NCAM), β-III-tubulin, NF70, nestin, CD271 (NGFR), CD29,
and HLA-ABC. The expression profiles were categorized as fol-
lows, based on the percentage of positive cells: 0–5% negative, 6–
39% low, 40–79%moderate, and 80–100% high. Flow cytometric
analysis revealed high levels of Nanog and SSEA-4 expression,
moderate levels of TRA-1-60, CD24, and β-III tubulin expres-
sion, and low levels of SSEA-1, nestin and HLA-ABC expression.
Undifferentiated hESCs were negative for several neuroectoder-
mal markers: CD133, NCAM, NF70, NGFR, and CD29.
The rationale behind this analysis is to show how undifferenti-
ated cells are positive for several pluripotent markers, but do not
express typical neural markers (Figure 1A).
DIFFERENTIATION INTO NEURAL PRECURSORS
The production of NPs can currently be obtained via three meth-
ods: (i) using a co-culture with a stromal cell line or stromal
feeder-based differentiation (Kawasaki et al., 2000; Vazin et al.,
2008; Kim and Park, 2011), (ii) using the recently more con-
ventional formation of embryoid bodies (EBs) (Lee et al., 2000),
which is also widely employed to differentiate stem cells into car-
diomyocytes (Burridge et al., 2007), or (iii) using the monolayer
culture system (Reubinoff et al., 2001; Chambers et al., 2009; Li
et al., 2011). The main advantage of the adherent monolayer pro-
tocol over the EB protocol is based on the rapidity of the time for
neural induction (6–9 vs. 16–19 days). However neural rosettes
cannot easily be distinguished and isolated with the monolayer
culture system.
It is worth mentioning at this point that not all neuro-
spheres are produced from a neural stem cell and can there-
fore be generated from neural progenitors; this may be an
issue in attempts to amplify cultures enriched in neural stem
cells. For this particular reason, the Neural Colony-Forming
Cell Assay was developed based on the capacity of single cells
to generate colonies of various sizes depending on their level
of differentiation (see Louis et al., 2008), which thus provides
a reliable tool to quantify neural stem cells in comparison to
progenitor cells. It is commercially available for neural colonies
derived from mouse embryonic central nervous system (CNS)
tissue.
For the derivation of neuroectodermal progenitors from the
CCTL14 line of hESCs an effective differentiation protocol was
developed based on the formation, propagation and expansion of
sphere cultures. After 14 days of induction, the NPs were further
passaged in a monolayer (Kozubenko et al., 2010).
The use of fetal calf serum and mouse feeder cells poten-
tially exposes the human cells to unknown pathogens (viruses
and prions), which might be transmitted between species.
Both serum and feeder cells may also contain many unde-
fined components that may influence the differentiation of
hESCs. The elimination of these factors from the culture
process is one of the major challenges in the develop-
ment of hESC culture systems and with regard to their fur-
ther application in translational medicine. The propagation
of hESCs, using mammalian- or human-derived extracellular
matrix and conditioned medium from feeder cells, may rep-
resent a potential approach to solve these issues (Datta et al.,
2013).
CHARACTERIZATION OF THE hESC-DERIVED NEURAL
PRECURSORS
To assess the success of the differentiation procedure in terms of
neuronal specification and corresponding yield, we used a com-
bination of assays based on the expression of molecular markers
and cell function.
EXPRESSION OF MOLECULAR MARKERS
After 5 and 8 passages, hESC-derived NPs underwent a flow cyto-
metric analysis using antibodies against: CD29, CD271 (neural
growth factor receptor), HLA-ABC, CD15 (SSEA-1), CD56 (neu-
ral cell adhesion molecule), CD24, CD133/1, CD133/2, Nanog,
TRA-1-60, SSEA-4, nestin, neurofilament 70 kDa (NF70), and
NCAM (Figure 1B). In parallel real-time PCR was performed
employing primers for: nestin, Nanog, Oct4, Cripto, AFP, Sox2,
SSEA-1, α-actin, VGEFR, Nodal, GATA4, and Prom1 (CD133).
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FIGURE 1 | Marker expression analysis. (A) This table summarizes the
expression of characteristic markers in different lines of human embryonic
stem cells. The data were taken from the European Human Pluripotent Stem
Cell Registry. RT, RT-PCR; FC, Flow cytometry; IHC, Immunocytochemistry/
Immunohistochemistry; A, Array; +, detected; −, not detected; +/−, weak
signal; N/A, not applicable. (B) Fluorescence-activated cell sorting profiles of
pluripotent and neural markers in undifferentiated hESCs and hESC-derived
NPs (P6–P10) during long-term propagation in vitro. The predifferentiation of
hESCs led to the downregulation of pluripotent markers (Nanog, SSEA-4,
SSEA-1, TRA-1-60, and CD24) and upregulation of neural markers (CD133,
NCAM, β-III tubulin, NF70, and nestin). Data presented in Kozubenko et al.
(2010) and Forostyak et al. (2013) were pooled and revised to prepare this figure.
To confirm the presence of NPs and the level of differ-
entiation, immunocytochemistry was employed with antibod-
ies targeted against synaptophysin, β-III tubulin, neurofilament
160 kDa (NF-160), GABA, and glutamate.
In an additional immunostaining investigation, we further
detected the following neural markers: NeuN, β-III tubulin,
GFAP, S100, OLIG, GS (Forostyak et al., 2013). Moreover we
provided evidence of the presence of important Ca2+-sensitive
channels: L-type voltage-gated Ca2+ channels (VGCC), P/Q-type
VGCC, Ryanodine receptor Ca2+ release channels (RyR) type
1, RyR2 (in only a few cells), and RyR3. Finally we could
detect the expression of the purinergic receptors P2X2, P2X3,
and P2X7, which work as substrates for the fast excitatory
neurotransmitter ATP.
CELL FUNCTION ASSAY
Patch-clamp experiments unveiled three main types of currents
in the hESC-derived NPs: (i) tetrodotoxin-sensitive currents,
indicative of functional voltage-gated Na+ channels, (ii) fast acti-
vating A-type K+ current and delayed outwardly rectifying K+
current, and (iii) GABA-evoked currents (Figure 2A). The rest-
ing membrane potential reached values of around −60mV 5
weeks after the induction of differentiation (Kozubenko et al.,
2010).
In addition, and as stipulated above, investigations
based on the measurements of the intracellular calcium
concentration ([Ca2+]i) in single cells showed and confirmed the
expression of functional VGCCs (Figure 2B), intracellular RyRs,
sarco-endoplasmic reticulum calcium-ATPase pumps, as well as
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FIGURE 2 | Functional characterization of neurones derived from human
stem cells. (A) CCTL14 hESC-derived neural precursors express a typical
neuronal current pattern in vitro. (a) Typical membrane current pattern of a
β-III tubulin-positive cell before and after the application of 1μM tetrodotoxin
and the tetrodotoxin-sensitive current. (b) The corresponding I/V relationship.
(c) Fast activating A-type K+ current (KA, red color) and delayed outwardly
rectifying K+ current (KDR, green color). (d) Corresponding I/V relationships
for KDR (filled circles) and KA (filled squares). (e) Action potential generation
by β-III tubulin-positive cells demonstrated by representative voltage
responses to an increasing current injection (in 10-pA steps). (f) GABA-evoked
currents (left) and corresponding I/V relationships for control traces prior to
(filled diamonds), during (filled squares), and after GABA washout (filled
triangles, right). Reproduced from Kozubenko et al. (2010) with kind
permission of Cognizant Communication Corporation (Putnam Valley, NY,
USA). (B) Voltage-operated Ca2+ channels in CCTL14-P7 hESC-derived neural
precursors. Examples of Fura-2 fluorescence traces (a–c) from individual cells
for each experimental design showing the block of 50mM K+ (applied 10 s,
see arrows) responses by specific Ca2+ channel antagonists. The cells were
first exposed to a control 50mM K+-induced depolarization and the [Ca2+]i
responses were monitored. Subsequently, the same cell was pre-incubated
for 5min with Ca2+ channel blockers (Cd2+/Ni2+, non-selective high and
low-VGCC; nicardipine, L-type blocker; ω-GVIA, N-type blocker and ω-MVIIC,
P/Q-type blocker) as indicated on the trace and then again challenged with
high K+. Pre-incubation of cells with 100μM Cd2+ together with 50μM Ni2+,
nicardipine 10μM and ω-conotoxin MVIIC (300 nM) significantly reduced the
(Continued)
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FIGURE 2 | Continued
[Ca2+]i responses (about 85, 54, and 92%, respectively; n = 5–9 for
each group). No significant inhibition (only about 20%) was observed in
the presence of N-type blocker, ω-conotoxin GVIA 800 nM (P = 0.27;
n = 9). The bar diagrams (d–g) are cumulative data showing the
reduction of high K+-induced [Ca2+]i responses by L- and P/Q-type
Ca2+ channel blockers (e and g). (∗P < 0.05, or ∗∗P < 0.001) vs. control
K+ stimulus. Data and figure revised from Forostyak et al. (2013) with
kind permission of Mary Ann Liebert, Inc., publishers (New Rochelle,
NY, USA).
FIGURE 3 | Roadmap for the use of hESCs in CNS regenerative
medicine. This simplified and summarized flowchart illustrates the major
important phases to obtain, differentiate and characterize a stem cell model
with regenerative potential for the CNS regarding stem cell-based therapy.
The experimental approaches of identification and characterization appear in
blue color, while the protocol for stem cell culture and differentiation appears
in black color. FACS, Fluorescence-activated cell sorting; IHC,
Immunohistochemistry. The figure was produced using Servier Medical Art.
glutamate and purinergic receptors. Moreover around 30% of the
hESC-derived NPs (passage 7) displayed a series of spontaneous
Ca2+ transients, referred to as oscillations, which were driven by
extracellular Ca2+ and VGCCs (mainly L-type) (Forostyak et al.,
2013).
Needless to mention, at this stage the full functional
characterization of the CCTL14-derived NPs is an on-going
process and further central points must be promptly addressed in
order to better understand the remodeling of the Ca2+ homeosta-
sis occurring during differentiation. Such central points include
www.frontiersin.org August 2014 | Volume 2 | Article 36 | 5
Viero et al. Characterization of neural stem cells
cell survival rate, the detailed quantification of the expressed
receptors and channels, the expression of specific GABA and
glutamate receptors, the role of inositol trisphosphate receptor-
mediated signaling pathways, and the developmental profile of
the resting [Ca2+]i.
A similar approach, conducted by our collaborators, was used
to test the stem cell model—an immortalized neural stem cell
line from human fetal spinal cord which preserves the features
of ventral spinal cord progenitors even after extensive in vitro
propagation and engraftment onto a lesioned rodent spinal cord
(Cocks et al., 2013). From the cell lines generated, individual SPC-
01-derived neurons exhibited similar Ca2+ signaling patterns to
what was described previously in the case of CCTL14-derived
NPs; particularly the presence of functional L- and P/Q-type Ca2+
channels and the occurrence of spontaneous Ca2+ oscillations.
TRANSPLANTATION ASSAY
The last examination consisted of monitoring the survival and
the differentiation of the hESC-NPs in vivo. For this purpose sin-
gle cell suspensions were injected into the striatum of rat brains
approximately 1 week after a stroke injury. The best results were
obtained with NPs (passage 8 or P8) in terms of elevated sur-
vival, low tumor formation, and capacity of cell migration toward
the lesion site (Kozubenko et al., 2010). These results were in
the agreement with the data obtained from functional studies,
showing that P7 and P8 were in the best physiological condi-
tions among other passages. Furthermore the fact that attempts
to engraft undifferentiated hESCs led to the formation of tumors
in all cases serves as a teratoma assay and confirms the capacity
of hESC pluripotency (Figure 3). Strikingly, prolonged periods
of cell culturing decreased the quality of the NPs with regard
to survival and migration. Finally it is worth mentioning that
implantation of SPC-01 cells (a conditionally immortalized neu-
ral stem cell line derived from human fetal spinal cord tissue,
see above) in Wistar rats resulted in distinct motor and sensory
restoration after spinal cord injury (Amemori et al., 2013).
In neurodegenerative conditions such as Parkinson’s and
Alzheimer’s diseases, engraftment experiments with stem cells
also yielded promising results (Sykova and Forostyak, 2013). The
transplantation of dopaminergic neurones derived from mouse
ESC obtained either by fertilization or by nuclear transfer cor-
rected the phenotype of mouse models of Parkinson’s disease
(Kim et al., 2002; Barberi et al., 2003). Moreover investiga-
tions employing human embryonic and transplanted neural stem
cells provided useful information on the normal functions of
Alzheimer’s disease-related genes, their role in neural develop-
ment, and therapeutic perspectives in animal models (Chen and
Blurton-Jones, 2012).
CONCLUSION
Here we summarized the information collected by our collabora-
tors over the last few years in order to present an outline for the
generation of a suitable human stem cell line for neural differ-
entiation and further transplantation. The huge amount of data
produced during the functional characterization of this cell line
will serve as an invaluable basis to define a thorough profiling of
the corresponding NPs. A unique ion channel and Ca2+ handling
footprint will be assigned to each line of hESC-NPS. Thus cells,
such as CCTL14-derived NPs, will participate in forming a pool
of models for human cells that can be employed for basic and
medical research, drug screening and cell therapy.
Beside the promising therapeutic strategies currently being
tested in animalmodels, an increasing number of studies based on
treatments of nervous system diseases by stem cells are entering
clinical trials all over the world. Indeed companies, hospitals and
universities have been approved to conduct Phase I clinical trials.
It has been recently pointed out though that large discrepancies in
the guidelines between the NIH Stem Cell registry and the FDA’s
requirements make the majority of hESC used not yet amenable
to be tested in clinical trials (Jonlin, 2014). However, the first
hESC-based treatment proposed by Advanced Cell Technology
for Stargardt’s Macular Dystrophy and Dry Age Related Macular
Degeneration (Schwartz et al., 2012) has already been authorized
by the FDA for Phase I/II clinical trials. In addition, Neuralstem, a
company using human spinal cord derived stem cells (from fetus,
not embryos) developed a therapy for amyotrophic lateral sclero-
sis which is currently being tested in Phase II clinical trials after
approval by the FDA.
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